Font size
WorksheetsGLP1-RA
Total questions: 10
Worksheet time: 5mins
Which of the following have demonstrated cardiovascular benefit compared with placebo?
Liraglutide
Oral semaglutide
SQ semaglutide
dulaglutide
exenatide
Which of the following is true of GLP-1 but not true of GIP?
Increases insulin secretion
Beta-cell sparing
Decreases glucagon secretion
Degraded by DPP-4
T/F: Long-acting agents have been shown to have a greater effect on both A1c reduction and weight loss.
True
False
T/F: You cannot be started on a GLP1-RA if you have ESRD.
True
False
The following GLP1-RA carries a risk of retinopathy:
semaglutide
dulaglutide
liraglutide
exenatide
Which of the following recommendations is true?
GLP-1RA are recommended in patients with a history of pancreatitis
GLP-1RA are recommended for patients with type 2 & type 1 diabetes
It is OK to take GLP-1RA with DPP-4 inhibitors, as long as you monitor for hypoglycemia
Patients with a history of thyroid cancer should avoid using GLP-1RA
T/F: There are no GLP1-RA products approved for weight loss.
True
False
Short-acting agents target ____ glucose while long-acting agents have _______.
post-prandial; a mixed effect
pre-prandial; a worse effect
fasting; a post-prandial effect
post-prandial; no effect
T/F: Injection site reactions are more common in long-acting agents as opposed to short-acting.
True
False
A 50 y/o overweight female with T2DM is currently on metformin 1 gm BID. Her post-prandial BG is not at goal and her A1C is 7.7%. She is terrified of needles and does not want to inject any medication. What option would benefit her the most at this time?
Change metformin to glipizide
Increase metformin to 850 mg TID
Oral semaglutide
Diet and exercise only
